Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$113.87 USD

113.87
314,806

-0.68 (-0.59%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $113.78 -0.09 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 251)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Is Jazz Pharmaceuticals a Great Stock for Value Investors?

Let's see if Jazz Pharmaceuticals (JAZZ) stock is a good choice for value-oriented investors right now from multiple angles.

    Is the Options Market Predicting a Spike in Jazz Pharmaceuticals (JAZZ) Stock?

    Investors need to pay close attention to Jazz Pharmaceuticals (JAZZ) stock based on the movements in the options market lately.

      Why Is Jazz (JAZZ) Down 2.4% Since Last Earnings Report?

      Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe

        Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.

          Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat

          Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.

            Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?

            Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.

              Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)

              Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

                Will Wdesk Cloud Platform Drive Workiva's (WK) Q2 Earnings?

                Workiva (WK) continues to focus on developing its flagship product, Wdesk cloud platform, which continues to gain traction.

                  Zillow Group (ZG) to Report Q2 Earnings: Is a Beat in Store?

                  Zillow Group (ZG) to benefit from strong growth of it's Premier Agent Business. We expect the company to gain from increasing traffic at its mobile apps and websites, strong rental demand and MLS partnerships.

                    ANSYS (ANSS) to Report Q2 Earnings: What's in the Offing?

                    Synergies from acquisitions are enabling ANSYS(ANSS) to bring innovative solutions to the market and also to enhance its foothold in the competitive simulations market.

                      What's in Store for Catalyst (CPRX) This Earnings Season?

                      Investors' focus will be on Catalyst's (CPRX) pipeline candidates, Firdapse and CPP-115, and regulatory updates, during the second-quarter earnings call.

                        Aerie (AERI) to Report Q2 Earnings: What's in the Offing?

                        Investors will focus on Rhopressa's initial uptake, and other pipeline and regulatory updates, when Aerie (AERI) reports Q2 results.

                          What's in Store for Intercept (ICPT) This Earnings Season?

                          Investors will primarily focus on Ocaliva's performance along with other pipeline developments, when Intercept (ICPT) reports its Q2 results on Aug 2.

                            Is a Beat in Store for Endocyte (ECYT) This Earnings Season?

                            The investor's focus is expected to remain on updates from pipeline candidates 177Lu-PSMA-617, CAR-T cell program during the Q2 earnings call.

                              5 Low Price-to-Book Stocks Worth Buying in July

                              P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

                                Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval

                                Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.

                                  Aclaris Stock Up on JAK Inhibitor's Encouraging Activity

                                  Aclaris Therapeutics (ACRS) posts positive interim data from a phase II study on its Alopecia Areata candidate, ATI-502.

                                    Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics

                                    Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.

                                      5 Stocks Near 52-Week High: Is More Upside in the Cards?

                                      Here are some stocks trading near their 52-week high levels with potential to scale higher.

                                        Jazz Pharmaceuticals' sNDA for Xyrem Gets Priority Review

                                        Jazz Pharmaceuticals' (JAZZ) label expansion application for Xyrem in pediatric patients gets priority review from the FDA.

                                          Swarup Gupta headshot

                                          5 Low-Beta Stocks to Buy as Trade Conflict Intensifies

                                          Since trade tensions could drastically dent investor confidence, picking value stocks with low-beta looks like a smart option at this point.

                                            Kinjel Shah headshot

                                            Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy

                                            Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.

                                              Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA

                                              Zacks.com highlights: Jazz Pharmaceuticals, Baxter International, Boise Cascade, Insight Enterprises and Comfort Systems USA

                                                5 Stocks Near 52-Week High With More Room to Run

                                                Here are some stocks trading near their 52-week high levels and still with plenty of room for upside.

                                                  5 Best Bargain PEG Stocks That Value Investors Love

                                                  While P/E alone fails to identify a true value stock, PEG helps to find the intrinsic value of a stock.